CTOs on the Move

Biohaven Pharmaceutical

www.biohavenpharma.com

 
Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Biohaven Pharmaceutical raised $80M on 11/01/2016
Biohaven Pharmaceutical raised $80M on 07/03/2017
Biohaven Pharmaceutical raised $200M on 03/15/2021

Similar Companies

Precigen

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Ventana Medical Systems

Ventana Medical Systems is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hamilton

The leader in liquid handling equipment and laboratory automation technology, Hamilton Robotics is recognized for advancing life science and biotechnology industries with products that offer reliability, performance and flexibility. Hamilton is the ind...

Zevra Therapeutics

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients lives.